Pregnant with COVID-19 and Rubella: Impact in the Maternal and Newborn Health

Case Report

Austin J Clin Immunol. 2021; 7(1):1042.

Pregnant with COVID-19 and Rubella: Impact in the Maternal and Newborn Health

Dias VC1, Bastos VQA2, Bastos LQA3, Bastos AN4, Bastos RV2, Silva VL1, Diniz CG1 and Ferreira-Machado AB1*

1Department of Parasitology, Microbiology and Immunology, Federal University of Juiz de Fora, Juiz de Fora, Brazil

2Cortes Villela Clinical Laboratory, Juiz de Fora, Brazil

3Department of Pathology, Federal University of Juiz de Fora, Juiz de Fora, Brazil

4Department of Morphology, Federal University of Juiz de Fora, Juiz de Fora, Brazil

*Corresponding author: Alessandra Barbosa Ferreira Machado, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil

Received: April 19, 2021; Accepted: June 02, 2021; Published: June 09, 2021

Abstract

Since December 2019, COVID-19 has become major global public health problem. The understanding of SARS-CoV-2, especially the effect on pregnant women and neonates, is still not fully elucidated. This report case describes a pregnant with COVID-19 and rubella. SARS-CoV-2 nucleic acid was not detected in the neonate just after birth, indicating that there was not vertical transmission. Although anti-SARS-CoV-2 Immunoglobulin G (IgG) antibody and anti-Rubella Virus IgG antibody were detected in the newborn serum, anti-SARS-CoV-2 (Immunoglobulin M) IgM and anti-Rubella Virus IgM were not detected. The observations may suggest transplacental transmission of coronavirus and rubella antibodies, ensuring immediate immunity against these pathogens to newborn.

Keywords: SARS-CoV-2; Rubella; Pregnant; Coinfection

Introduction

COVID-19 is an infection disease caused by SARS-CoV-2 [1]. The clinical manifestations may include fever, difficulty in breathing, cough, coryza, sore throat, loss of smell and taste and even death from multiple organ failure. The first case was reported in December 2019 in Wuhan, China and has spread around the world at an accelerated rate, included Brazil. At present, scarce information is still available on the clinical and epidemiological outcomes of COVID-19 in pregnancy. Additionally, the COVID-19 pandemic has raised concerns about the possibility of mother-fetal vertical intrauterine transmission [2,3], coinfection with others microorganisms and the impact in the maternal and newborn health. This report case describes a Brazilian pregnant with COVID-19 (tested positive at the 28th week of pregnancy) and also positive for rubella (detected in 31st week). SARS-CoV-2 nucleic acid was not detected in the neonate nasopharyngeal swab, suggesting no vertical transmission. However, further laboratory analysis revealed anti-SARS-CoV-2 IgG antibody and anti-rubella IgG antibody in the newborn serum. This case may suggest transplacental transmission of protective antibodies against SARS-CoV-2 and rubella virus ensuring immediate immunity against these pathogens to newborn.

Case Presentation

A 33-year-old Brazilian 28-week pregnant woman with loss of smell and taste was diagnosed with COVID-19 by Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR). At this time, the patient did not present respiratory symptoms (runny nose, cough, fever or respiratory distress), diarrhea and myalgia. Additionally, anti-Rubella Virus IgM and IgG antibodies were detected in the pregnant woman’s serum, indicating recent viral infection. Laboratory screening for HIV, hepatitis B, hepatitis C, toxoplasmosis, cytomegalovirus, and syphilis tested negative in the same sample. During the pregnancy, hematological tests (platelets, leukocytes, erythrocytes, hemoglobin, hematocrit), glucose, vitamins (B12 and D), ferritin, lactic dehydrogenase, d-dimer, C-reactive protein, thromboplastin time, prothrombin time, Thyroid-Stimulating Hormone (TSH) and Thyroxine (T4) showed results within the reference values indicated for their age and gender (Table 1A). After 14 days of COVID-19 positive test, the patient presented increased fibrinogen (acute phase protein), suggesting an increase in the inflammatory process (Table 1A). On the day of delivery, a nasopharyngeal swab was collected from the newborn and nucleic acid was not detected by RT-qPCR, indicating that there was no vertical transmission of SARS-CoV-2. Anti-SARSCoV- 2 IgG and anti-Rubella Virus IgG antibody were detected in the newborn serum. However, Anti-SARS-CoV-2 IgM and anti- Rubella Virus IgM antibody were not detected. These observations may suggest transplacental transmission of coronavirus and rubella antibodies, ensuring immediate immunity against these pathogens to newborn. Laboratory screening for HIV and syphilis of the newborn showed negative results. Bilirubin dosage showed to be elevated. Phenylalanine, neonatal hemoglobinplasty, TSH, 17 alpha hydroxyprogesterone, trypsin, t4, biotinidase, glucose-6-phosphate dehydrogenase (G6PD) deficiency, amino acid chromatography, galactose, toxoplasmosis were negative or within the expected range for the age group (Table 1B).

Citation: Dias VC, Bastos VQA, Bastos LQA, Bastos AN, Bastos RV, Silva VL, et al. Pregnant with COVID-19 and Rubella: Impact in the Maternal and Newborn Health. Austin J Clin Immunol. 2021; 7(1):1042.